(2026). Summary of Research: Economic Benefit of Aflibercept 8 mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US. Ophthalmology and Therapy.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Summary of Research: Economic Benefit of Aflibercept 8 Mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US."
Ophthalmology and Therapy 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Summary of Research: Economic Benefit of Aflibercept 8 Mg Versus Faricimab for Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema in the US."
Ophthalmology and Therapy, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.